Small Cell Lung Cancer

Patients with advanced or metastatic non–small cell lung cancer (NSCLC) were able to specify a 1-point threshold when describing meaningful symptom change, for better or worse, that helped illustrate their symptom experience.

Investigators wanted to analyze the diagnostic performance of methylation-sensitive restriction enzyme digestion followed by sequencing using cell-free DNA and explore the cancer signal origin of the cancer using DNN analyses for colorectal and lung cancers.

Removal of pulmonary function tests (PFTs) might exacerbate disparities for African American patients with lung cancer.

Certain immune cell types are associated with immune checkpoint inhibitor (ICI) response in patients with non–small cell lung cancer (NSCLC).

Patients with non-small cell lung cancer (NSCLC) with a high risk of brain metastases might feasibly be identified through machine-learning models, according to a recent study.

Patients with RET fusion-positive advanced or metastatic non–small cell lung cancer had a survival benefit when treated with selpercatinib in the LIBRETTO-431 study.

The process from referral to the lung cancer screening (LCS) process is a crucial point for Black veterans and may serve as a point of improvement, according to a study.

In an interview with Targeted Oncology, Sagun Shrestha, MD, evaluated new developments and clinical trials for patients with extensive-stage small cell lung cancer.

Coverage from the Institute for Value-Based Medicine event in Atlanta, held in partnership with Winship Cancer Institute of Emory University.

Wildfire smoke is associated with worse survival for individuals with non–small cell lung cancer (NSCLC) who are recovering from surgical resection treatment.

Analysis suggests tumor histology plays an important role in determining the best first-line approach for patients who have non–small cell lung cancer (NSCLC).

Prediction models are needed to identify individuals at high risk for lung cancer who are former smokers and for whom low-dose computed tomography screening is not recommended, according to one study.

Researchers assessed public posts on websites to better understand the experiences of patients with non–small cell lung cancer (NSCLC).

Amivantamab-vmjw (Rybrevant) showed efficacy in a phase 3 trial of patients with newly diagnosed advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation.

Patients with small cell lung cancer (SCLC) with fewer than 5 brain metastases fared better than those with more than 5 when treated with stereotactic radiosurgery (SRS).

A retrospective case series study suggests that standardized guidelines for reporting and managing significant incidental findings (SIFs) in low-dose computed tomography (LDCT) lung cancer screening could help optimize the treatment of patients whose LDCT scans show SIFs.

Investigators found no significant impact on survival, however.

The majority of patients had prior experience with telemedicine, but none had experience with telerehabilitation.

Abstracts were presented in a session on metastatic lung cancer on the final day of the 2023 American Society of Clinical Oncology Annual Meeting.

A session chaired by ASCO and ESMO leadership included experts on the latest lung and colorectal cancer screening technologies and persistent disparities in screening access and uptake.

The phase 3 LUNAR trial evaluating tumor treating fields (TTFields) with standard-of-care therapies met its primary end point in patients with metastatic non–small cell lung cancer (NSCLC).

A study presented at the American Society of Clinical Oncology Annual Meeting found practice- and provider-level racial and ethnic inequities in rates of next-generation sequencing (NGS) testing for patients with advanced non–small cell lung cancer (NSCLC) treated in the community setting.

High circulating tumor DNA (ctDNA) tumor fraction after induction chemotherapy identifies a population with an unmet need who has low chances to benefit from immune checkpoint blockades for non–small cell lung cancer (NSCLC), according to research discussed during a presentation at the American Society of Clinical Oncology Annual Meeting.

An abstract at the American Society of Clinical Oncology Annual Meeting showed disparities in lung cancer screening rates in an urban, multiethnic community, and patient navigation increased rates overall.

Former and current smokers showed higher mortality from early-stage non-small cell lung cancer than never smokers.

Thomas Stricker, MD, PhD, and Gregory Vidal, MD, PhD, are both first authors on their respective abstracts involving patients with advanced non-small cell lung cancer in the community setting.

Researchers took both the learning curve of the new process and the COVID-19 pandemic into consideration.

Compared with first-line immunotherapy or chemotherapy alone, combination chemoimmunotherapy for advanced/metastatic non–small cell lung cancer has significantly higher antineoplastic drug and associated medical costs.

Osimertinib plus chemotherapy showed a statistically significant improvement in progression-free survival (PFS) vs osimertinib alone in patients with epidermal growth factor receptor–mutated (EGFRm) advanced non–small cell lung cancer (NSCLC)